Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/aging.202742 http://scihub22266oqcxt.onion/10.18632/aging.202742 33744863!8034918!33744863     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33744863&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Aging+(Albany+NY) 2021 ; 13 (6): 7745-7757 Nephropedia Template TP {{tp|p=33744863|t=2021. Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis |pdf=|usr=}}{{33744863}} gab.com Text Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis JO: Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33744863 #FOAvip Coronavirus disease 2019 (COVID-19) has infected tens of millions of people worldwide within the last year. However, the incidence of fungal co-infection in COVID-19 patients remains unclear. To investigate the association between fungal co-infection and mortality due to COVID-19, we systematically searched Medline, Embase, MedRxiv and Cochrane Library for eligible studies published in the period from 1 January to 1 December 2020. We performed a meta-analysis of nine studies that met the inclusion criteria. In total, data from 2780 patients and 426 patients were included who were admitted to the ICU. In eight of the articles, 211 participants died due to COVID-19 infection, which means an overall mortality rate of 10.9%. The overall pooled proportion of fungal co-infection in COVID-19 patients was 0.12 (95% CI = 0.07-0.16, n = 2780, I(2) = 96.8%). In terms of mortality in COVID-19 patients with fungal infection, the overall pooled proportion of mortality was 0.17 (95% CI = 0.10-0.24, n = 1944, I(2) = 95.6%). These findings provide evidence suggesting a favorable use for empirical antibiotics in the majority of patients when COVID-19 infection is diagnosed. Our analysis is investigating the use of antifungal therapy to treat COVID-19 can serve as a comprehensive reference for COVID-19 treatment. Twit Text FOAVip Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis ????Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33744863 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33744863 #FOAvip English Wikipedia <ref>{{Cite pmid|33744863}}</ref> Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis #MMPMID33744863 Peng J; Wang Q; Mei H; Zheng H; Liang G; She X; Liu W Aging (Albany NY) 2021[Mar]; 13 (6): 7745-7757 PMID33744863show ga Coronavirus disease 2019 (COVID-19) has infected tens of millions of people worldwide within the last year. However, the incidence of fungal co-infection in COVID-19 patients remains unclear. To investigate the association between fungal co-infection and mortality due to COVID-19, we systematically searched Medline, Embase, MedRxiv and Cochrane Library for eligible studies published in the period from 1 January to 1 December 2020. We performed a meta-analysis of nine studies that met the inclusion criteria. In total, data from 2780 patients and 426 patients were included who were admitted to the ICU. In eight of the articles, 211 participants died due to COVID-19 infection, which means an overall mortality rate of 10.9%. The overall pooled proportion of fungal co-infection in COVID-19 patients was 0.12 (95% CI = 0.07-0.16, n = 2780, I(2) = 96.8%). In terms of mortality in COVID-19 patients with fungal infection, the overall pooled proportion of mortality was 0.17 (95% CI = 0.10-0.24, n = 1944, I(2) = 95.6%). These findings provide evidence suggesting a favorable use for empirical antibiotics in the majority of patients when COVID-19 infection is diagnosed. Our analysis is investigating the use of antifungal therapy to treat COVID-19 can serve as a comprehensive reference for COVID-19 treatment. |Antifungal Agents/therapeutic use[MESH] |COVID-19/*complications/mortality/virology[MESH] |Humans[MESH] |Intensive Care Units[MESH] |Mycoses/*complications/drug therapy[MESH] |Patient Admission[MESH]Fungal co-infection in COVID-19 patients: evidence from a systematic r(epmc).pdf DeepDyve Pubget Overpricing